

The Medicines Company

[View the current The Medicines Company Page on BioPortfolio.com](http://www.bioportfolio.com/bi corporate/30995-The+Medicines+Company.html)

(<http://www.bioportfolio.com/bi corporate/30995-The+Medicines+Company.html>)

Contact Details:

8 Campus Drive

Parsippany

New Jersey

07054

United States of America

Tel:

Fax:

Email: alliances@themedco.com

The Medicines Company meets the demands of the world's most advanced medical practitioners by developing products that improve acute hospital care. The Company markets Angiomax® (bivalirudin) for injection, an anticoagulant approved for use in patients undergoing coronary angioplasty procedures. The Medicines Company creates value using its range of clinical and commercial skills to develop products acquired from leading life science innovators.

The Company is publicly traded on the Nasdaq exchange under the ticker symbol MDCO. It was founded in 1996 and employs approximately 250 professionals.

Recent Publications by The Medicines Company:



- [Impact of human serum albumin on oritavancin in vitro activity against Staphylococcus aureus.](#)
*Human serum albumin (HSA) did not affect oritavancin MICs against...*7th November, 2009
Anti-Infective Unit, The Medicines Company, St. Laurent, Quebec H4S 2A1,- Diagn Microbiol Infect Dis. 2009 Oct;65(2):207-10. ([DOI Direct Link](#))
- [Time-kill kinetics of oritavancin and comparator agents against Streptococcus pyogenes.](#)
*The activity of oritavancin in vitro against recent clinical isolates of...*13th October, 2009
The Medicines Company, St Laurent, Quebec, Canada.- Int J Antimicrob Agents. 2009 Dec;34(6):550-4. Epub 2009 Oct 8. ([DOI Direct Link](#))
- [Comparative in vitro activity of oritavancin against recent, genetically diverse, community-associated methicillin-resistant Staphylococcus aureus \(MRSA\) isolates.](#)
*Human serum albumin (HSA) did not affect oritavancin MICs against...*12th September, 2009
The Medicines Company, 7170 Frederick Banting Street, Second Floor, Ville- Int J Antimicrob Agents. 2009 Sep 8. ([DOI Direct Link](#))
- [Comparative in vitro activity profile of oritavancin against recent gram-positive clinical isolates.](#)

Oritavancin activity was tested against 15,764 gram-positive isolates... 10th September, 2009
The Medicines Company, 7170 Frederick Banting Street, Second Floor, Saint- Antimicrob Agents
Chemother. 2009 Nov;53(11):4762-71. Epub 2009 Sep 8. ([DOI Direct Link](#))

- [Use of IHC and newly designed matriptase inhibitors to elucidate the role of matriptase in pancreatic ductal adenocarcinoma.](#)

Matriptase, also known as MT-SP1, is a type II transmembrane serine... 2nd September, 2009
The Medicines Company (Leipzig) GmbH, D-04103 Leipzig, Germany.- Int J Oncol. 2009
Aug;35(2):347-57.

- [Incorporation of neutral C-terminal residues in 3-amidinophenylalanine-derived matriptase inhibitors.](#)
A novel series of matriptase inhibitors based on previously identified... 16th June, 2009
The Medicines Company (Leipzig) GmbH, Deutscher Platz 5d, D-04103 Leipzig,- Bioorg Med Chem
Lett. 2009 Apr 1;19(7):1960-5. Epub 2009 Feb 14. ([DOI Direct Link](#))

- [Aspirin to prevent cardiovascular disease: the association of aspirin dose and clopidogrel with thrombosis and bleeding.](#)

BACKGROUND: The optimal aspirin dose for the prevention of cardiovascular... 9th April, 2009
The Medicines Company, Balsberg, 8058 Zurich-Flughafen, Switzerland.- Ann Intern Med. 2009 Mar
17;150(6):379-86.

- [Sample size re-estimation for adaptive sequential design in clinical trials.](#)

There is considerable interest in methods that use accumulated data to... 23rd January, 2009
Biostatistics, The Medicines Company, Parsippany, New Jersey 07054, USA.- J Biopharm Stat.
2008;18(6):1184-96. ([DOI Direct Link](#))

- [Assessing non-inferiority: a combination approach.](#)

Non-inferiority designs are growing in importance as a strategy for... 25th April, 2008
The Medicines Company, 8 Campus Drive, Parsippany, NJ 07054, USA.- Stat Med. 2008 Feb
10;27(3):392-406. ([DOI Direct Link](#))

- [What is the proper activated clotting time \(ACT\) at which to remove a femoral sheath after PCI? What are the best "protocols" for sheath removal?](#)

Non-inferiority designs are growing in importance as a strategy for... 13th July, 2005
The Medicines Company, Waltham, Mass, USA.- Crit Care Nurse. 2005 Apr;25(2):88-92, 94-5.

- [Multiple-dose pharmacokinetics of intranasally administered IS-159 in healthy subjects.](#)

This study was designed to investigate the multiple-dose pharmacokinetics... 8th October, 2003
The Medicines Company, Gasstrasse 1, CH-4056 Basel, Switzerland.- Eur J Drug Metab
Pharmacokinet. 2003 Jan-Mar;28(1):49-54.

Press Releases on The Medicines Company:

[Frost & Sullivan Award
Underlines Cipla
Medpro's Status as
Company of the Year in
the South African Generic
Pharmaceutical Market](#)

26th November, 2009 Frost & Sullivan

JOHANNESBURG, South Africa,
Nov. 26 /PRNewswire/ -- The
2009 Frost & Sullivan South
Africa Company of the Year
Award in the Generic
Pharmaceutical Market is
presented to Cipla Medpro South
Africa

New Hologic SecurView(R) DX Diagnostic Workstation Software Streamlines Workflow, Improves Radiologist Productivity	25th November, 2009 Hologic, Inc.	<i>BEDFORD, Mass., Nov. 25 /PRNewswire-FirstCall/ -- Hologic, Inc. (Hologic or the Company) (Nasdaq: HOLX), a leading developer, manufacturer and supplier of premium diagnostics, medical imaging systems</i>
American Scientific Resources Inc. Opens Shanghai Location	25th November, 2009 American Scientific Resources, Inc.	<i>WESTON, Fla., Nov. 25 /PRNewswire-FirstCall/ -- American Scientific Resources Inc. (Pink Sheets: ASFX) ("the Company") is pleased to announce that they have opened a regional marketing and</i>
Dakota Growers Pasta Company Authorizes Dividend	25th November, 2009 Dakota Growers Pasta Company, Inc.	<i>CARRINGTON, N.D., Nov. 25 /PRNewswire/ -- The Board of Directors of Dakota Growers Pasta Company, Inc. has authorized the payment of non-periodic dividends of \$0.62 per share on its Common Stock, \$0</i>
ERT to Present at the 21st Annual Piper Jaffray Health Care Conference on December 1, 2009	25th November, 2009 ERT	<i>PHILADELPHIA, Nov. 25 /PRNewswire-FirstCall/ -- ERT (Nasdaq: ERES), announced today that Dr. Michael J. McKelvey, the Company's President and CEO, and Keith Schneck, the Company's Executive</i>

BioNews Results for The Medicines Company



- [Tongjitang Chinese Medicines Company Post 3Q Financial Results](#)
Individual.com: Nov 21 2009 6:40AM Matching: medicines company
- [Monitoring Force GmbH Requests Acknowledgment of Flibanserin as 'Orphan Drug'](#)
Pharma Live: Nov 21 2009 5:16AM Matching: medicines company
- [New gastric cancer drug approved](#)
Pharmacy Europe: Nov 20 2009 6:27PM Matching: medicines company
- [Medical News: Daschle Still Making Voice Heard On Health Care](#)
BioFind: Nov 20 2009 4:52PM Matching: medicines company
- [Medical News: Daschle Still Making Voice Heard On Health Care](#)
BioFind: Nov 20 2009 4:51PM Matching: medicines company
- [Merck Receives CHMP Positive Opinion for New Fertility Treatment...](#)
Zibb: Nov 20 2009 2:26PM Matching: medicines company

- [EU Approves Advanced Gastric Cancer Treatment](#)
Pharmaceutical Technology: Nov 20 2009 12:29PM Matching: medicines company
- [MONITORING FORCE GmbH Requests Acknowledgment of Flibanserin as 'Orphan Drug'](#)
KOTA Territory News: Nov 20 2009 10:37AM Matching: medicines company
- [Angel Biotechnology : Successful completion of MRHA](#)
Investigate: Nov 20 2009 7:43AM Matching: medicines company
- [News and FDA Updates for Tongjitang \(NYSE:TCM\), YM BioSciences \(NYSE:YMI\), Pfizer \(NYSE:PFE\)](#)
California Chronicle: Nov 20 2009 4:44AM Matching: medicines company
- [News and FDA Updates for Tongjitang \(NYSE:TCM\), YM BioSciences \(NYSE:YMI\), Pfizer \(NYSE:PFE\)](#)
American Chronicle: Nov 20 2009 1:10AM Matching: medicines company
- [MONITORING FORCE GmbH Requests Acknowledgment of Flibanserin as 'Orphan Drug'](#)
Pharmacy Choice: Nov 19 2009 9:36PM Matching: medicines company
- [News and FDA Updates for Tongjitang \(NYSE:TCM\), YM BioSciences \(NYSE:YMI\), Pfizer \(NYSE:PFE\)](#)
Los Angeles Chronicle: Nov 19 2009 9:16PM Matching: medicines company
- [Otsuka Pharma Europe Withdraws Abilify Extension Application](#)
Morningstar.com: Nov 19 2009 5:30PM Matching: medicines company
- [BiomedReports: News and FDA Updates for Tongjitang \(NYSE:TCM\), YM BioSciences \(NYSE:YMI\), Pfizer \(NYSE:PFE\)](#)
TradingMarkets: Nov 19 2009 4:16PM Matching: medicines company

BioCorporate Profiles - upgrade to a full profile

BioPortfolio's BioCorporate full profiles offers your organization the opportunity to increase internet traffic to your corporate web site and enhance awareness of your business, technology, products and services. BioCorporate profiles are dynamic and are updated weekly with new information sourced from core information resources: publications, clinical trials, patents and global news.

Why you should upgrade your BioPortfolio BioCorporate profile:

- the ability to amend and add information on products and services to your profile using a membership username and password
- the option to add a corporate logo
- the creation of high value URL links back to your organization's website which will improve search engine ranking - resulting in increased site traffic
- the option have your press releases published on BioPortfolio and distributed via our BioNewsCast service
- an enhanced BioCorporate profile will also improve your exposure on BioPortfolio's related service InDepth and GeneDB

The annual cost is \$995.00 for established organizations and \$495.00 for organizations less than 12 months old.

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Stafford House, 10 Prince of Wales Road, Dorchester, Dorset, DT1 1PW, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2009 - BioPortfolio Limited.

